{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T00:19:26Z","timestamp":1793319566661,"version":"4.5.0"},"reference-count":78,"publisher":"American Medical Association (AMA)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA"],"published-print":{"date-parts":[[2025,8,12]]},"abstract":"<jats:sec id=\"ab-jrv250011-1\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Immune thrombotic thrombocytopenic purpura (iTTP) is a life-threatening thrombotic microangiopathy that presents with microangiopathic hemolytic anemia (MAHA) and thrombocytopenia. Worldwide annual incidence of iTTP is 2 cases per million to 6 cases per million.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250011-2\">\n                    <jats:title>Observations<\/jats:title>\n                    <jats:p>\n                      Immune TTP is caused by an autoantibody to a disintegrin and metallopeptidase with thrombospondin type 1 motif 13 (ADAMTS13), an enzyme that cleaves von Willebrand factor (vWF). With severely low ADAMTS13 activity (&amp;amp;lt;10%), large multimers of vWF accumulate and bind platelets, forming microvasculature thromboses that cause ischemic organ injury (eg, myocardial infarction and stroke). The incidence of iTTP is higher in adults than children (incident rate ratio [IRR], 31.62 per million person-years [95% CI, 14.68-68.10]), females than males (IRR, 3.19 [95% CI, 2.65-3.85]), and Black compared with non-Black individuals (IRR, 7.09 [95% CI, 6.05-8.31]). Common presenting symptoms are neurologic (eg, headache, confusion, or seizures [39%-80%]) and abdominal pain (35%-39%). For patients presenting with MAHA and thrombocytopenia, clinical prediction scores for iTTP using laboratory data, such as platelet count less than 30\u2009\u00d7\u200910\n                      <jats:sup>9<\/jats:sup>\n                      \/L and creatinine level less than 2.0 mg\/dL (176.8 \u03bcmol\/L), can help guide empirical treatment initiation for iTTP before ADAMTS13 results are available. Prompt initiation of therapy with therapeutic plasma exchange, corticosteroids, and rituximab improves survival with iTTP from almost zero to approximately 93%. Caplacizumab, a synthetic small antibody (nanobody) that blocks platelet binding to vWF, administered concurrently with immunosuppression and therapeutic plasma exchange and continued until ADAMTS13 recovery, reduces the time to normalization of platelet count and decreases the risk of early recurrence (defined as within 30 days of completing therapeutic plasma exchange) compared with placebo (risk difference [RD], \u221229% [95% CI, \u221242 to \u221214%]) but increases bleeding risk (RD, 17% [95% CI, 4%-30%]). After obtaining clinical remission (defined as at least 30 days of sustained normalization of platelet count, decreased serum lactate dehydrogenase level, and absence of new or progressive ischemic organ injury without therapeutic plasma exchange or caplacizumab), 16% of patients have at least 1 relapse of iTTP. Regular monitoring of ADAMTS13 activity in remission and administration of rituximab when ADAMTS13 activity is less than 20% reduces risk of relapse (odds ratio, 0.09 [95% CI, 0.04-0.24]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-jrv250011-3\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>Immune TTP is a rare immune-mediated disorder that presents with thrombocytopenia and MAHA and may cause life-threatening thrombosis. Treatment with therapeutic plasma exchange, corticosteroids, and rituximab is associated with 30-day survival rates of more than 90%. Addition of caplacizumab shortens time to normalization of platelet count and reduces recurrences while receiving the drug but increases bleeding risk. Monitoring ADAMTS13 activity in survivors and initiation of rituximab for those with low ADAMTS13 activity reduces the risk of clinical relapse.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jama.2025.3807","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:31:27Z","timestamp":1747654287000},"page":"517","source":"Crossref","is-referenced-by-count":53,"title":["Immune Thrombotic Thrombocytopenic Purpura"],"prefix":"10.1001","volume":"334","author":[{"given":"Allyson M.","family":"Pishko","sequence":"first","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ang","family":"Li","sequence":"additional","affiliation":[{"name":"Section of Hematology-Oncology, Baylor College of Medicine, Houston, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[{"name":"Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"},{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"22","key":"jrv250011r1","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1056\/NEJM199811263392203","article-title":"Antibodies to von Willebrand factor-cleaving protease in acute thrombotic thrombocytopenic purpura.","volume":"339","author":"Tsai","year":"1998","journal-title":"N Engl J Med"},{"issue":"3","key":"jrv250011r2","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1182\/blood.2019004221","article-title":"Open ADAMTS13, induced by antibodies, is a biomarker for subclinical immune-mediated thrombotic thrombocytopenic purpura.","volume":"136","author":"Roose","year":"2020","journal-title":"Blood"},{"issue":"3","key":"jrv250011r3","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1182\/bloodadvances.2023010807","article-title":"A descriptive analysis of fatal outcomes in immune thrombotic thrombocytopenic purpura in the USTMA TTP Registry.","volume":"8","author":"Abou-Ismail","year":"2024","journal-title":"Blood Adv"},{"issue":"10","key":"jrv250011r4","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1182\/blood-2017-04-636431","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura.","volume":"130","author":"Sadler","year":"2017","journal-title":"Blood"},{"issue":"3","key":"jrv250011r5","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/blood.2022017023","article-title":"Long-term risk of relapse in immune-mediated thrombotic thrombocytopenic purpura and the role of anti-CD20 therapy.","volume":"141","author":"Doyle","year":"2023","journal-title":"Blood"},{"issue":"5","key":"jrv250011r6","doi-asserted-by":"publisher","first-page":"e237","DOI":"10.1016\/S2352-3026(16)30018-7","article-title":"Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy.","volume":"3","author":"Mariotte","year":"2016","journal-title":"Lancet Haematol"},{"issue":"10","key":"jrv250011r7","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1002\/pbc.24612","article-title":"Children and adults with thrombotic thrombocytopenic purpura associated with severe, acquired ADAMTS13 deficiency: comparison of incidence, demographic and clinical features.","volume":"60","author":"Reese","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"jrv250011r8","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13023-019-1240-0","article-title":"Incidence of acquired thrombotic thrombocytopenic purpura in Germany: a hospital level study.","volume":"14","author":"Miesbach","year":"2019","journal-title":"Orphanet J Rare Dis"},{"issue":"1","key":"jrv250011r9","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1182\/asheducation-2018.1.530","article-title":"Clinical and laboratory diagnosis of TTP: an integrated approach.","volume":"2018","author":"Chiasakul","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"10","key":"jrv250011r10","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1182\/bloodadvances.2017005124","article-title":"Thrombotic thrombocytopenic purpura: diagnostic criteria, clinical features, and long-term outcomes from 1995 through 2015.","volume":"1","author":"Page","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"jrv250011r11","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1111\/bjh.13658","article-title":"Impact of severe ADAMTS13 deficiency on clinical presentation and outcomes in patients with thrombotic microangiopathies: the experience of the Harvard TMA Research Collaborative.","volume":"171","author":"Bendapudi","year":"2015","journal-title":"Br J Haematol"},{"issue":"14","key":"jrv250011r12","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1182\/blood.2020009150","article-title":"Redefining outcomes in immune TTP: an international working group consensus report.","volume":"137","author":"Cuker","year":"2021","journal-title":"Blood"},{"issue":"6","key":"jrv250011r13","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1111\/ijlh.13682","article-title":"2021 update of the 2012 ICSH Recommendations for identification, diagnostic value, and quantitation of schistocytes: impact and revisions.","volume":"43","author":"Zini","year":"2021","journal-title":"Int J Lab Hematol"},{"issue":"10","key":"jrv250011r14","doi-asserted-by":"publisher","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"5","key":"jrv250011r15","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1111\/bjh.13654","article-title":"The utility of ADAMTS13 in differentiating TTP from other acute thrombotic microangiopathies: results from the UK TTP Registry.","volume":"171","author":"Hassan","year":"2015","journal-title":"Br J Haematol"},{"issue":"6","key":"jrv250011r16","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1111\/ijlh.13295","article-title":"International Council for Standardization in Haematology (ICSH) recommendations for laboratory measurement of ADAMTS13.","volume":"42","author":"Mackie","year":"2020","journal-title":"Int J Lab Hematol"},{"issue":"3","key":"jrv250011r17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1160\/TH12-08-0565","article-title":"Discrepancies between ADAMTS13 activity assays in patients with thrombotic microangiopathies.","volume":"109","author":"Mackie","year":"2013","journal-title":"Thromb Haemost"},{"issue":"1","key":"jrv250011r18","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1111\/trf.12762","article-title":"Diagnostic and prognostic values of ADAMTS13 activity measured during daily plasma exchange therapy in patients with acquired thrombotic thrombocytopenic purpura.","volume":"55","author":"Wu","year":"2015","journal-title":"Transfusion"},{"issue":"7","key":"jrv250011r19","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1111\/jth.14815","article-title":"A multi-center evaluation of TECHNOSCREEN\u00ae ADAMTS-13 activity assay as a screening tool for detecting deficiency of ADAMTS-13.","volume":"18","author":"Moore","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"jrv250011r20","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2023.100108","article-title":"ADAMTS13 activity testing: evaluation of commercial platforms for diagnosis and monitoring of thrombotic thrombocytopenic purpura.","volume":"7","author":"Singh","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"jrv250011r21","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1111\/jth.15157","article-title":"A multicenter laboratory assessment of a new automated chemiluminescent assay for ADAMTS13 activity.","volume":"19","author":"Favaloro","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"3","key":"jrv250011r22","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/ijlh.13414","article-title":"Multicentric evaluation of the new HemosIL Acustar\u00ae chemiluminescence ADAMTS13 activity assay.","volume":"43","author":"Pascual","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"jrv250011r23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2024.285391","article-title":"Acquired thrombotic thrombocytopenic purpura without detectable anti-ADAMTS13 antibodies: a possible underlying autoimmune mechanism.","author":"Simon","year":"2024","journal-title":"Haematologica"},{"issue":"1","key":"jrv250011r24","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12863-021-01010-0","article-title":"The global carrier frequency and genetic prevalence of Upshaw-Schulman syndrome.","volume":"22","author":"Zhao","year":"2021","journal-title":"BMC Genom Data"},{"issue":"4","key":"jrv250011r25","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/S2352-3026(17)30026-1","article-title":"Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study.","volume":"4","author":"Bendapudi","year":"2017","journal-title":"Lancet Haematol"},{"issue":"19","key":"jrv250011r26","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1182\/blood.2020005221","article-title":"Management of thrombotic microangiopathy in pregnancy and postpartum: report from an international working group.","volume":"136","author":"Fakhouri","year":"2020","journal-title":"Blood"},{"issue":"5","key":"jrv250011r27","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1111\/bjh.17099","article-title":"Clinical features of vitamin B12 deficiency mimicking thrombotic microangiopathy.","volume":"191","author":"Koshy","year":"2020","journal-title":"Br J Haematol"},{"issue":"1","key":"jrv250011r28","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.transci.2018.01.003","article-title":"Cobalamin deficiency presenting with thrombotic microangiopathy (TMA) features: a systematic review.","volume":"57","author":"Tran","year":"2018","journal-title":"Transfus Apher Sci"},{"issue":"9","key":"jrv250011r29","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1111\/trf.15954","article-title":"Diagnostic accuracy of the PLASMIC score in patients with suspected thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"60","author":"Paydary","year":"2020","journal-title":"Transfusion"},{"issue":"4","key":"jrv250011r30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010208","article-title":"Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA reference center experience.","volume":"5","author":"Coppo","year":"2010","journal-title":"PLoS One"},{"issue":"1","key":"jrv250011r31","doi-asserted-by":"publisher","first-page":"266","DOI":"10.1111\/trf.16188","article-title":"Reduced sensitivity of PLASMIC and French scores for the diagnosis of thrombotic thrombocytopenic purpura in older individuals.","volume":"61","author":"Liu","year":"2021","journal-title":"Transfusion"},{"issue":"4","key":"jrv250011r32","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1056\/NEJMoa1806311","article-title":"Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura.","volume":"380","author":"Scully","year":"2019","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv250011r33","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura.","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"issue":"10","key":"jrv250011r35","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.1111\/jth.15010","article-title":"ISTH guidelines for treatment of thrombotic thrombocytopenic purpura.","volume":"18","author":"Zheng","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"23","key":"jrv250011r36","doi-asserted-by":"publisher","first-page":"2075","DOI":"10.1182\/bloodadvances.2017009308","article-title":"Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura.","volume":"1","author":"Cataland","year":"2017","journal-title":"Blood Adv"},{"key":"jrv250011r37","doi-asserted-by":"publisher","DOI":"10.1177\/1076029618825309","article-title":"Comparison of the long-term remission of rituximab and conventional treatment for acquired thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"25","author":"Owattanapanich","year":"2019","journal-title":"Clin Appl Thromb Hemost"},{"issue":"8","key":"jrv250011r38","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1182\/bloodadvances.2020001834","article-title":"Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis.","volume":"5","author":"Peyvandi","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"jrv250011r39","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/bloodadvances.2022008443","article-title":"Adding caplacizumab to standard of care in thrombotic thrombocytopenic purpura: a systematic review and meta-analysis.","volume":"7","author":"Djulbegovic","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"jrv250011r40","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1056\/NEJM199108083250604","article-title":"Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura.","volume":"325","author":"Rock","year":"1991","journal-title":"N Engl J Med"},{"issue":"6","key":"jrv250011r41","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1056\/NEJM199108083250605","article-title":"Improved survival in thrombotic thrombocytopenic purpura-hemolytic uremic syndrome: clinical experience in 108 patients.","volume":"325","author":"Bell","year":"1991","journal-title":"N Engl J Med"},{"issue":"8","key":"jrv250011r42","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1046\/j.1537-2995.2000.40080896.x","article-title":"Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura-hemolytic-uremic syndrome.","volume":"40","author":"Rizvi","year":"2000","journal-title":"Transfusion"},{"issue":"4","key":"jrv250011r43","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1111\/trf.15721","article-title":"Deaths and complications associated with the management of acute immune thrombotic thrombocytopenic purpura.","volume":"60","author":"Colling","year":"2020","journal-title":"Transfusion"},{"issue":"4","key":"jrv250011r44","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/bjh.19026","article-title":"A British Society for Haematology guideline: diagnosis and management of thrombotic thrombocytopenic purpura and thrombotic microangiopathies.","volume":"203","author":"Scully","year":"2023","journal-title":"Br J Haematol"},{"issue":"5","key":"jrv250011r45","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1182\/blood.2021014514","article-title":"How I treat immune-mediated thrombotic thrombocytopenic purpura after hospital discharge.","volume":"140","author":"Akwaa","year":"2022","journal-title":"Blood"},{"issue":"7","key":"jrv250011r46","doi-asserted-by":"publisher","first-page":"1746","DOI":"10.1182\/blood-2011-03-341131","article-title":"A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura.","volume":"118","author":"Scully","year":"2011","journal-title":"Blood"},{"issue":"24","key":"jrv250011r47","doi-asserted-by":"publisher","first-page":"3092","DOI":"10.1182\/blood-2016-03-703827","article-title":"Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura.","volume":"127","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"13","key":"jrv250011r48","doi-asserted-by":"publisher","first-page":"1106","DOI":"10.1182\/blood.2019000795","article-title":"Adjuvant low-dose rituximab and plasma exchange for acquired TTP.","volume":"134","author":"Zwicker","year":"2019","journal-title":"Blood"},{"issue":"2","key":"jrv250011r49","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"AGA clinical practice guideline on the prevention and treatment of hepatitis B virus reactivation in at-risk individuals.","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"2","key":"jrv250011r50","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1111\/bjh.18192","article-title":"The use of obinutuzumab and ofatumumab in the treatment of immune thrombotic thrombocytopenic purpura.","volume":"198","author":"Doyle","year":"2022","journal-title":"Br J Haematol"},{"key":"jrv250011r52","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2025.103168","article-title":"Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective cohort study (the Capla 1000+ project).","volume":"82","author":"Coppo","year":"2025","journal-title":"eClinicalMedicine"},{"issue":"13","key":"jrv250011r53","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1182\/bloodadvances.2020001987","article-title":"ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP.","volume":"4","author":"V\u00f6lker","year":"2020","journal-title":"Blood Adv"},{"issue":"14","key":"jrv250011r54","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1182\/blood.2023023780","article-title":"Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange.","volume":"144","author":"K\u00fchne","year":"2024","journal-title":"Blood"},{"issue":"13","key":"jrv250011r55","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1182\/blood.2020007599","article-title":"Real-world experience with caplacizumab in the management of acute TTP.","volume":"137","author":"Dutt","year":"2021","journal-title":"Blood"},{"issue":"24","key":"jrv250011r56","doi-asserted-by":"publisher","first-page":"6219","DOI":"10.1182\/bloodadvances.2022008028","article-title":"Real-world effectiveness of caplacizumab vs the standard of care in immune thrombotic thrombocytopenic purpura.","volume":"6","author":"Izquierdo","year":"2022","journal-title":"Blood Adv"},{"issue":"25","key":"jrv250011r57","doi-asserted-by":"publisher","first-page":"3860","DOI":"10.1182\/blood-2014-11-551580","article-title":"How I treat refractory thrombotic thrombocytopenic purpura.","volume":"125","author":"Sayani","year":"2015","journal-title":"Blood"},{"issue":"1","key":"jrv250011r58","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1097\/CCM.0b013e31822e9d66","article-title":"Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange.","volume":"40","author":"Froissart","year":"2012","journal-title":"Crit Care Med"},{"issue":"3","key":"jrv250011r59","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1182\/bloodadvances.2021005124","article-title":"Daratumumab for immune thrombotic thrombocytopenic purpura.","volume":"6","author":"van den Berg","year":"2022","journal-title":"Blood Adv"},{"issue":"2","key":"jrv250011r60","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jtha.2024.10.034","article-title":"Bortezomib for rituximab-refractory immune-mediated thrombotic thrombocytopenic purpura in the caplacizumab era: an Italian multicenter study.","volume":"23","author":"Giannotta","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"20","key":"jrv250011r61","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1182\/blood-2018-04-840090","article-title":"Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.","volume":"132","author":"Jestin","year":"2018","journal-title":"Blood"},{"issue":"17","key":"jrv250011r62","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1182\/blood-2016-06-724161","article-title":"Clinical importance of ADAMTS13 activity during remission in patients with acquired thrombotic thrombocytopenic purpura.","volume":"128","author":"Page","year":"2016","journal-title":"Blood"},{"issue":"2","key":"jrv250011r63","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1182\/blood-2014-01-550244","article-title":"Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura.","volume":"124","author":"Hie","year":"2014","journal-title":"Blood"},{"issue":"4","key":"jrv250011r64","doi-asserted-by":"publisher","first-page":"294","DOI":"10.7326\/0003-4819-125-4-199608150-00006","article-title":"Splenectomy done during hematologic remission to prevent relapse in patients with thrombotic thrombocytopenic purpura.","volume":"125","author":"Crowther","year":"1996","journal-title":"Ann Intern Med"},{"issue":"5","key":"jrv250011r65","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1111\/j.1365-2141.2005.05681.x","article-title":"Splenectomy for the treatment of thrombotic thrombocytopenic purpura.","volume":"130","author":"Kappers-Klunne","year":"2005","journal-title":"Br J Haematol"},{"issue":"2","key":"jrv250011r66","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/jca.10053","article-title":"Role of splenectomy in patients with refractory or relapsed thrombotic thrombocytopenic purpura.","volume":"18","author":"Aqui","year":"2003","journal-title":"J Clin Apher"},{"issue":"12","key":"jrv250011r67","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1002\/ajh.20678","article-title":"Outcomes in the treatment of thrombotic thrombocytopenic purpura with splenectomy: a retrospective cohort study.","volume":"81","author":"Outschoorn","year":"2006","journal-title":"Am J Hematol"},{"issue":"5","key":"jrv250011r68","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/BF01784041","article-title":"The role of splenectomy in the treatment of relapsing thrombotic thrombocytopenic purpura.","volume":"70","author":"Veltman","year":"1995","journal-title":"Ann Hematol"},{"issue":"2","key":"jrv250011r69","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1111\/ejh.13886","article-title":"Preemptive cyclosporin A in immune-mediated thrombotic thrombocytopenic purpura.","volume":"110","author":"Comparon","year":"2023","journal-title":"Eur J Haematol"},{"issue":"23","key":"jrv250011r70","doi-asserted-by":"publisher","first-page":"3469","DOI":"10.1182\/blood-2014-04-561142","article-title":"The splenic autoimmune response to ADAMTS13 in thrombotic thrombocytopenic purpura contains recurrent antigen-binding CDR3 motifs.","volume":"124","author":"Schaller","year":"2014","journal-title":"Blood"},{"issue":"3","key":"jrv250011r71","doi-asserted-by":"publisher","first-page":"E73","DOI":"10.1002\/ajh.25002","article-title":"No major differences in outcomes between the initial and relapse episodes in patients with thrombotic thrombocytopenic purpura: the experience from the Ohio State University Registry.","volume":"93","author":"Masias","year":"2018","journal-title":"Am J Hematol"},{"issue":"8","key":"jrv250011r72","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.3324\/haematol.2011.049676","article-title":"Development and validation of a predictive model for death in acquired severe ADAMTS13 deficiency-associated idiopathic thrombotic thrombocytopenic purpura: the French TMA Reference Center experience.","volume":"97","author":"Benhamou","year":"2012","journal-title":"Haematologica"},{"issue":"4","key":"jrv250011r73","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1182\/blood-2016-12-758656","article-title":"Presenting ADAMTS13 antibody and antigen levels predict prognosis in immune-mediated thrombotic thrombocytopenic purpura.","volume":"130","author":"Alwan","year":"2017","journal-title":"Blood"},{"issue":"4","key":"jrv250011r74","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1182\/bloodadvances.2020004169","article-title":"Cardiovascular disease is a leading cause of mortality among TTP survivors in clinical remission.","volume":"6","author":"Sukumar","year":"2022","journal-title":"Blood Adv"},{"issue":"13","key":"jrv250011r75","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood.2019001056","article-title":"Reduced ADAMTS13 activity during TTP remission is associated with stroke in TTP survivors.","volume":"134","author":"Upreti","year":"2019","journal-title":"Blood"},{"issue":"24","key":"jrv250011r76","doi-asserted-by":"publisher","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura.","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"issue":"2","key":"jrv250011r77","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1182\/blood-2014-02-553131","article-title":"Thrombotic thrombocytopenic purpura and pregnancy: presentation, management, and subsequent pregnancy outcomes.","volume":"124","author":"Scully","year":"2014","journal-title":"Blood"},{"issue":"5","key":"jrv250011r78","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1182\/blood-2010-07-295444","article-title":"Pregnancy outcomes after maternal exposure to rituximab.","volume":"117","author":"Chakravarty","year":"2011","journal-title":"Blood"},{"key":"jrv250011r34","unstructured":"Rituximab. Prescribing information. US Food and Drug Administration. Updated December 2021. Accessed March 2, 2025. https:\/\/www.accessdata.fda.gov\/spl\/data\/3a716937-c2af-4bf9-976c-c34746b22ff0\/3a716937-c2af-4bf9-976c-c34746b22ff0.xml#S6.1"},{"key":"jrv250011r51","unstructured":"Caplacizumab-yhdp. Prescribing information. US Food and Drug Administration. February 2019. Accessed January 23, 2025. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/761112Orig1s000ltr.pdf"}],"container-title":["JAMA"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/articlepdf\/2834159\/jama_pishko_2025_rv_250011_1753989311.99733.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T15:19:05Z","timestamp":1755011945000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jama\/fullarticle\/2834159"}},"subtitle":["A Review"],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.1001\/jama.2025.3807","relation":{},"ISSN":["0098-7484"],"issn-type":[{"value":"0098-7484","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}